Background: N-Acetylcysteine (NAC), an antioxidative reagent for clinical diseases, shows potential in the treatment of diabetes and other metabolic diseases. However, it is unknown how NAC modulates the gut microbiota of mice with metabolic syndrome. The aim of the present study was to demonstrate the preventive effect of NAC on intestinal dysbiosis and glucose metabolic disorder. Methods: Mice (C57BL/6J strain) were fed either a normal chow diet (NCD), NCD plus NAC, a high-fat diet (HFD), or HFD plus NAC for 5 months, after which glucose levels, circulating endotoxins and key metabolism-related proteins were determined. Fecal samples were analyzed by 16S rRNA sequencing. A novel analysis was performed to predict functional changes in gut microbiota. In addition, Spearman's correlation analysis was performed between metabolic biomarkers and bacterial abundance. Results: Treatment with NAC significantly reversed the glucose intolerance, fasting glucose concentrations, and gains in body weight and plasma endotoxin in HFD-fed mice. Further, NAC upregulated occludin and mucin glycoprotein levels in the proximal colon of HFD-treated mice. Noticeably, NAC promoted the growth of beneficial bacteria (i.e. Akkermansia, Bifidobacterium, Lactobacillus and Allobaculum) and decreased populations of diabetes-related genera, including Desulfovibrio and Blautia. In addition, NAC may affect the metabolic pathways of intestinal bacteria, including lipopolysaccharide biosynthesis, oxidative stress, and bacterial motility. Finally, the modified gut microbiota was closely associated with the metabolic changes in NAC-treated HFD-fed mice. Conclusions: N-Acetylcysteine may be a potential drug to prevent glucose metabolic disturbances by reshaping the structure of the gut microbiota.
Introduction
In recent years, the population of diabetic and obese people has increased sharply. It was estimated by the seventh edition of the Diabetes Atlas (http://www. diabetesatlas.org, accessed 10th October 2017) that, in 2015, the number of diabetic adults around the world was almost triple the number in 2000, reaching a total of 415 million, which has led to heavy financial burdens for both individuals and nations. Regretfully, this chronic metabolic disease is still not under control. Further, solid evidence shows that modern life, characterized by longer sedentary time and excess consumption of energy-dense food, has led to a higher incidence of metabolic syndrome, including overweight, adiposity, systemic inflammation, and insulin resistance. [1] [2] [3] It has been reported that gut microbiota can influence metabolic processes and may be an environmental factor contributing to obesity and its comorbidities. 4 Studies indicate that the configuration of the gut microbiota has a strong connection with the obese phenotype, 5 and that individuals with pronounced metabolic dysfunction and low-grade inflammation have reduced bacterial gene richness in the gut. 6, 7 Thus, interventions targeting gut dysbiosis may help patients restore their microbial gene richness and improve some clinical phenotypes. 6 So far, some prebiotics have been shown to be potential candidates for diabetes treatment. 8 For example, polyphenols, antioxidative reagents, are regarded as nutrient supplements to promote the growth of Akkermansia muciniphila and reduce the occurrence of diabetes mellitus or obesity. 9 In addition, metformin, the first-line drug treatment against type 2 diabetes mellitus, was proven to reverse gut dysbiosis. 10 Together, these findings highlight the importance of host-commensal interactions in diabetes treatment.
N-Acetylcysteine (NAC) is a potent antioxidative reagent 11 that is transformed into a precursor of reduced glutathione (GSH) after metabolism by hepatic cells. 12 Because of strong scavenging activities against various free radicals, NAC has been used as clinically for the treatment of paracetamol overdose, mucolytic therapy, and psychiatric disorders. 11 In addition, NAC can exert anti-inflammatory effects by reducing nuclear translocation of nuclear factor (NF)-κB. 13 Because both oxidative stress and the inflammatory reaction are important risk factors for diabetes and obesity, NAC has the potential to be used for the treatment of diabetes.
14 Indeed, NAC has been shown to effectively suppress glucose intolerance and insulin resistance in diabetic mice and humans. 12, 15 In addition, NAC exhibits a broad antibiofilm effect towards Streptococcus pneumoniae and Haemophilus influenzae, 16, 17 indicating a curative effect on gut dysbiosis. So far, there have been limited studies on the effects of NAC on the community structure and function of gut microbiota. 18 In consideration of the favorable therapeutic effect of NAC on diabetes mellitus, it is of importance to determine the role of gut microbiota in the prevention of diabetes and obesity by NAC.
In the present study we tested the hypothesis that NAC modulates the composition and function of intestinal bacteria, which further benefits metabolic syndrome in high-fat diet (HFD)-fed mice. To this end, we evaluated the effects of NAC on glucose intolerance of HFD-induced obese mice. In addition, we determined changes in the composition of gut microbiota in mice at different taxonomic levels. Finally, we used prediction tools to estimate the host's outcome as affected by the gut microbiota, and the potential interaction between intestinal bacteria and metabolic function.
Methods

Materials
N-Acetylcysteine was purchased from Acros Organic (Fairlawn, NJ, USA). Heparin sodium and fluorescein isothiocyanate-conjugated wheat germ agglutinin (WGA-FITC) were purchased from Sigma Aldrich (St Louis, MO, USA). An Accu-Chek glucometer was purchased from Roche Diagnostics (Rotkreuz, Switzerland). The normal chow diet (NCD; 10% fat; D12450B) and HFD (45% fat; D12451) were purchased from KeAo Xieli (Beijing, China). Antibodies against occludin and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other reagents were of the highest analytical grade.
Experimental design
Twenty adult mice aged 4-6 weeks (mean [AESD] weight 22 AE 1 g) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). All mice were housed under controlled environmental conditions under a 12-h light-dark cycle and fed standard diet and water at libitum for 1 week. After the 1-week acclimation period, the mice were randomly divided into four groups (n = 5 in each group): (i) an NCD-fed group; (ii) an HFD-fed group; (iii) an NAC (1 mg/mL, in drinking water)-treated NCD-fed group; and (iv) an NAC-treated HFD-fed group. Mice were fed the different diets for 5 months. During the treatment period, the body weight and dietary and water intake of mice were monitored. To insure that the bioactivity of NAC was not destroyed in drinking water, the NAC-containing water solution was changed every other day. After 5 months treatment, all mice were killed. After the mice were killed, serum was immediately isolated from blood samples and fecal samples were collected. All samples were stored at −80 C until use.
This study was performed in accordance with the National Act on Use of Experimental Animals (China). The study protocol was approved by the Committee on the Ethics of Animal Experiments of Institute of Process Engineering, Chinese Academy of Science (Permit no. SYXK2015-0002).
Intraperitoneal glucose tolerance test
An intraperitoneal glucose tolerance test (IGTT) was performed as reported previously, 9 with minor modifications. After 5 months treatment, all mice were fasted overnight and the IGTT was performed by intraperitoneal injection of glucose (1 g/kg). Glucose concentrations in blood samples collected from the tail vein were determined using an Accu-Chek glucometer before (0 min) and after (15, 30, 60 , and 120 min) glucose injection.
Analysis of blood samples and colon tissues
After the 5-month treatment period and completion of the IGTT, all mice were killed. Blood samples, adipose tissues and the large intestine were collected. Whole blood cell analysis was performed on a hematology analyzer (Nihon Kohden, Tokyo, Japan). Blood lipopolysaccharide (LPS) concentrations were determined using a mouse LPS ELISA kit (BlueGene Biotech, Shanghai, China), whereas western blotting and immunofluorescence analyses of proximal colon tissues were performed as described previously. 19 Extraction of DNA and polymerase chain reaction amplification After mice had been killed, fecal samples were collected and genomic DNA was extracted using a FastDNA SPIN Kit (MP Biomedicals, Santa Ana, CA, USA) according to the manufacturer's instructions. The quality of the DNA was checked by agarose gel electrophoresis and by determining the ratio of absorbance at 260 nm/280 nm. Further, the V3-V4 hypervariable region of the bacterial 16S rRNA gene were amplified using common primers fused to barcodes: 338F, 5 0 -ACTCCTACGGGAGGCAGCAG-3 0 (forward); and 806R, 5 0 -GACTACHVGGGTWTCTAAT-3 0 (reverse Amplicon quantitation, pooling, and sequencing Amplicons were extracted from 2% agarose gels, purified using an AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA) according to the manufacturer's instructions, and quantified using QuantiFluor-ST (Promega, Madison, WI, USA). The purified amplicons were pooled in equimolar ratios and paired-end sequenced (2 × 300) on an Illumina MiSeq platform according to standard protocols.
Sequences analysis
The extracted high-quality sequences were first analyzed using Quantitative Insights Into Microbial Ecology (QIIME) version 1.8 (http://qiime.org/, accessed 6 March 2016). Sequences were assembled and selected using the following criteria: (i) longer than 110 nucleotides; (ii) sequences with an overlap longer than 10 bp; (iii) an average quality score > 20 in every 50-bp sliding window; (iv) no mismatch with primers; and (v) no ambiguous characters. The unique sequence set was clustered into operational taxonomic units (OTUs) with the minimum threshold identity of 97% using UCLUST version 1.2.22 (http://www.drive5.com/uclust/downloads1_2_22q. html, accessed 15 March 2016). Chimeric sequences were identified and discarded using Usearch version 8.1.1861 (http://www.drive5.com/usearch/, accessed 16 March 2016). The taxonomy of each 16S rRNA gene sequence was analyzed by UCLUST against the Silva 16S rRNA database (release 119; http://www.arb-silva.de, accessed 20 March 2016) using a minimum threshold of 90% confidence. Finally, an OTU table was generated for relative abundance plots and further analysis.
Advanced analysis
To determine the significantly important microbial taxa, linear discriminant analysis effect size (LEfSe) analysis was performed as reported previously. 20 To explore the functional profile of the bacterial community dataset, a bioinformatic tool was used that predicted the gene family abundance based on a 16S gene survey, given a database of phylogenetically referenced genomes (phylogenetic investigation of communities by reconstruction of unobserved states [PICRUSt] ). 21 
Statistical analysis
Results are presented as the mean AE SEM. The significance of differences between two groups was determined by unpaired two-tailed Students' t-test, with P < 0.05 considered significant. Data were analyzed using GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA, USA). The LEfSe analysis related to the relative abundance of gut microbiota to total bacteria was based on Kruskal-Wallis and Wilcoxon tests, and the threshold on linear discriminant analysis (LDA) score was 4.0-5.0. Changes in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were plotted using STAMP software (Genome Atlantic, Halifax, Canada). Other results (principal component analysis [PCA] , non-metric multidimensional scaling [nMDS] , and heat maps) were plotted using R packages (R Foundation for Statistical Computing, Vienna, Austria).
Results
Effects of NAC on hyperglycemia in HFD-fed mice
To investigate the antidiabetic effect of NAC in mice, an in vivo study was performed. The C57BL/6J mice were fed with HFD to create a model of metabolic syndrome, and the HFD-fed mice were then treated with NAC (1 mg/mL, in drinking water) for 5 months. As shown in Fig. 1a , NAC treatment decreased the body weight of mice fed either the HFD or NCD. Compared with the HFD group, body weight gain was significantly decreased in the HFD-NAC group (P < 0.01 vs the HFD group; Fig. 1b) .
To assess the inhibitory effect of NAC on hyperglycemia, fasting glucose levels were monitored throughout the experimental period. In HFD-fed mice, hyperglycemia was markedly decreased after NAC treatment for 5 months (P < 0.01 vs HFD group; Fig. 1c ). In addition, the IGTT, an important index of type 2 diabetes mellitus, was performed. The IGTT showed that the elevated glucose intolerance in HFD-fed mice was significantly reversed by NAC treatment (P < 0.05 or 0.01 vs the HFD group; Fig. 1d ). In addition, the increase in the area under the glucose tolerance curve in the HFD group was suppressed by NAC treatment (P < 0.05 vs the HFD group; Fig. 1e ). Finally, NAC also reduced the increased mass of abdominal adipose tissues (including epididymal and mesenteric fat masses) in HFD-fed mice (P < 0.05 vs the HFD group; Fig. 1f ).
Effects of NAC on the hematological index and plasma LPS in HFD-fed mice
To determine the effects of NAC treatment on the hematological index in HFD-fed mice, a whole blood cell count was performed. As indicated in Table 1 , there was no significant difference in the red blood cell population between the four experimental groups. Compared with the NCD group, the mice fed the HFD had higher levels of white blood cells, which was reduced by NAC treatment (P < 0.05 vs the HFD group; Table 1) . Further, we calculated the amount of lymphocytes and monocytes as a percentage of white blood cells; NAC treatment significantly decreased the increased ratio of lymphocytes in HFD-fed mice (P < 0.05 vs the HFD group; Table 1 ). In addition, there was a marked increase in plasma LPS concentrations in HFD-fed mice, which was reversed by NAC treatment (Table 1) . Finally, NAC treatment attenuated the elevated levels of inflammatory markers, namely tumor necrosis factor-α, interleukin-6, and integrin alpha X (CD11c), of white adipose tissue (the methods and primers are described in File S1 and Table S1, whereas the results are shown in Fig. S1 , available as Supplementary Material to this paper).
Effects of NAC on damage to the intestinal barrier in HFD-fed mice
To determine whether NAC treatment alleviated endotoxin release from host intestine, the gut barrier was evaluated using western blotting and immunofluorescence analysis. Levels of the key tight junction protein occludin were determined. As shown in Fig. 2a,b , the decreased occludin levels in HFD-fed mice were significantly reversed by NAC treatment (P < 0.05 vs the HFD group). Further, the glycoprotein mucin, a critical component of the mucus layer, was detected using WGA-FITC (Fig. 2c) . The marked decrease in mucin glycoproteins in HFD-fed mice was significantly reversed by NAC treatment (Fig. 2c) . These results indicate that NAC may block the leakage of LPS by consolidating the gut barrier.
Structural modulation by NAC of gut microbiota in HFD-fed mice
To confirm whether NAC treatment affected the structure of the gut microbiota community, next-generation sequencing was performed based on the V3-V4 region of bacterial 16S rRNA. Using the Illumina MiSeq platform, 20 samples generated 1 032 524 raw tags. After removing low-quality sequences, the remaining 951 764 clean reads were used for further analysis, and all effective reads were clustered into OTUs. There was no significant difference in the number of OTUs between HFD-and NCD-fed mice (Fig. S2a) . However, NAC treatment significantly promoted the number of OTUs in mice fed the NCD or HFD (Fig. S2a) . In parallel, the abundance of observed species was increased either in the sequencing period (Fig. S2b) or at the end point (Fig. S2c) . In addition, the α-diversity Chao1 index showed that bacterial diversity in the HFD group was significantly decreased compared with that in the NCD group (P < 0.05), but was significantly promoted by NAC treatment (P < 0.01 vs the HFD group; Fig. S2d ). Interestingly, NAC treatment increased both bacterial richness and diversity in mice in the NCD group (P < 0.05 or 0.01 vs the NCD group; Fig. S2c,d ).
Effects of NAC on gut microbial community composition in HFD-fed mice
To evaluate the improvement in gut dysbiosis following NAC treatment, the β-diversity of bacteria was analyzed. Principal component analysis (PCA) was performed based on the OTU composition of each experimental group. The main findings were that different diets led to the development of different microbial communities, and that mice in the HFD-NAC group formed a cluster distinct from the HFD group (Fig. 3a) . Using another algorithm (i.e. nMDS analysis) revealed distinct clustering for each group (Fig. 3b) . At the phylum level, NAC treatment significantly upregulated the decreased levels of Firmicutes and Verrucomicrobia in HFD-fed mice, and significantly suppressed the growth of Bacteroidetes and the pathogenenriched phylum Proteobacteria (Fig. 3c) . At the genus level, NAC treatment increased the abundance of beneficial bacteria in HFD-fed mice, including Akkermansia (Fig. 4a) , Allobaculum (Fig. 4b) , Bifidobacterium (Fig. 4c) , Lactobacillus (Fig. 4d) , and Bacteroides (Fig. 4e) . Meanwhile, the abundance of Desulfovibrio (Fig. 4f ) , Blautia (Fig. 4g) , Intestinimonas (Fig. 4h) , and Odoribacter (Fig. 4i) was notably reduced by NAC treatment.
Next, to determine which bacterial families contributed to the difference in microbial composition between the four groups, comparisons at the Family level were displayed on a heat map representing the relative abundance of each family. As shown in Fig. 5 , changes in the abundance of 12 families accounted for the differences in the microbial community between mice in HFD-NAC and HFD groups, specifically Verrucomicrobiaceae, Desulfovibrionaceae, Lactobacillaceae, Bifidobacteriaceae, Erysipelotrichaceae, Porphystrepotococcaceae, Bacteroidaceae, Clostridiales vadin BB60 group, Clostridiaceae 1, Family XIII, Streptococcaceae, and Deferribacteraceae.
The results of LEfSe analysis showing the bacteria contributed to the gut mirobiota variety are displayed in Fig. 6 . Six families dominated the gut microbiota in mice of the HFD group: Porphyromonadaceae, Deferribacteraceae, Clostridiales vadin BB60 group, Aerococcaceae, Peptostreptococcaceae, and Desulfovibrionaceae. In contrast, there were several different families that greatly contributed to the intestinal microbiota community in mice of the HFD-NAC group, namely Corynebacteriaceae, Bacteroidaceae, Enterococcaceae, Leuconostocaceae, Streptococcaceae, Eubacteriaceae, Clostridiales family XIII, Peptostreptococcaceae, and Enterobacteriaceae (Fig. 6a) . Furthermore, LDA scores identified the major bacteria that were biomarkers of each group (Fig. 6b ): Lactobacillus and Bifidobacterium for the NCD group, Akkermansia and Lachnospiraceae UCG-006 for the NCD-NAC group, Desulfovibrio and Ruminiclostridium 9 for the HFD group, and Coriobacteriaceae UCG-002 and Bacteroides for the HFD-NAC group.
Effects of NAC on metabolic pathways of gut microbiota in HFD-fed mice
To determine the effect of NAC treatment on metabolic pathways of gut microbiota in HFD-fed mice, PICRUSt analysis was performed based on the microbiota composition of each experimental group. As shown in Fig. 7 , among 328 KEGG pathways at Level 3 KEGG Orthologies, 19 pathways were significantly changed in HFDfed mice; these pathways were related to bacterial behavior, host metabolism, and oxidative stress (Fig. 7a) . NAcetylcysteine treatment had no significant effect on these 19 pathways in NCD-fed mice (Fig. S3 ). In contrast, NAC treatment reverted 14 of the altered pathways to a certain extent in HFD-fed mice, with the affected pathways associated with bacterial motility activity (bacterial motility proteins, bacterial chemotaxis, flagellar assembly), metabolism (energy metabolism, lipid biosynthesis proteins, pantothenate and coenzyme A [CoA] biosynthesis, inorganic ion transport and metabolism, bile acid synthesis), and the redox system (DNA repair and recombination proteins, base excision repair, flavonoid metabolism; Fig. 7b ). In particular, NAC treatment totally restored cysteine, methionine, and glutathione metabolism pathways in HFD-fed mice (Fig. 7b) .
Correlation analyses between gut microbiota and metabolic biomarkers
To confirm the relationship between the altered gut microbiota composition and host metabolism, Spearman's correlation analysis was performed, with results shown as a heat map (Fig. 8 ). There were generally beneficial and detrimental clusters based on correlation coefficients (Fig. 8) .
Among them, the Intestinimonas, Desulfovibrio, Blautia, Odoribacter, and Streptococcus genera were positively correlated with hyperglycemia and high endotoxin levels (Fig. 8) . Other genera, namely Allobaculum, Akkermansia, Lactobacillus, Bifidobacterium, and Bacteroides, showed negative correlations with glucose intolerance and LPS concentrations, but positive correlations with occludin ( Fig. 8) . Further, the eight bacterial genera (Intestinimonas, Desulfovibrio, Blautia, Allobaculum, Akkermansia, Lactobacillus, Bifidobacterium, and Bacteroides) showed a closer association with metabolic indices (Fig. 8) .
Discussion
Several studies have reported on the antidiabetic effect of NAC in vivo. 12, 14 To the best of our knowledge, there are no reports of the modulatory effects of NAC on gut dysbiosis with diabetes mellitus. In the present Figure 3 Effects of N-acetylcysteine (NAC; 1 mg/mL, in drinking water) on the clustering and phylum composition of the gut microbial community in high-fat diet (HFD)-fed mice. Mice (C57BL/6J strain) were fed either a normal chow diet (NCD), HFD, NCD plus NAC or HFD plus NAC for 5 months. Then, fecal samples were collected from each group for 16S rRNA sequencing analysis based on V3-V4 region. β-Diversity analysis was performed, including (a) principle component analysis and (b) non-metric multidimensional scaling. PC, principal component; MDS, multidimensional scaling. (c) Relative abundance (to total bacteria) of predominant intestinal bacteria at the phylum level.
study we demonstrated that NAC largely reshaped the structure of the gut microbiota and improved the disturbance in glucose metabolism in HFD-fed mice.
During the entire experimental period, no apparent abnormal behavior was found in NAC-treated mice. In previous clinical studies, some side effects were observed after NAC treatment against aminoglycosideinduced ototoxicity for more than 6 weeks, such as abdominal pain, nausea, vomiting and diarrhea. [22] [23] [24] In the future studies, the toxic effects of NAC after longterm treatment should be further evaluated.
Inflammation is one of the important hallmarks of obesity and diabetes, and is usually initiated by serum LPS, a key metabolite of intestinal bacteria. 25 Studies show that NAC exerts potent suppressive effects on inflammatory responses and oxidative stress, and is confirmed to be favorable for diabetes amelioration. 11, 14 Previous reports indicate that the white blood cells have a positive relationship with metabolic syndrome, 26 and that endotoxin was an independent risk factor for metabolic diseases. 27 The results of the present study confirm the anti-inflammatory effects of NAC, which reduced the Figure 4 Effects of N-acetylcysteine (NAC; 1 mg/mL, in drinking water) on the composition of the gut microbial community at the genus level in high-fat diet (HFD)-fed mice. Mice (C57BL/6J strain) were fed either a normal chow diet (NCD), HFD, NCD plus NAC or HFD plus NAC for 5 months. Then, fecal samples were collected (n = 5) from each group for 16S rRNA sequencing analysis based on the V3-V4 region. (a) Akkermansia, (b) Allobaculum, (c) Bifidobacterium, (d) Lactobacillus, (e) Bacteroides, (f) Desulfovibrio (g) Blautia, (h) Intestinimonas, and (i) Odoribacter were assayed. The boxes show the interquartile range, with the median value indicated by the horizontal line; whiskers show the range. *P < 0.05, **P < 0.01 compared with the NCD group; † P < 0.05, † † P < 0.01 compared with the HFD group.
population of lymphocytes (Table 1) , decreased the circulating serum LPS concentrations in HFD-fed mice (Table 1) , and attenuated adipose inflammation (Fig. S1) . Conversely, the gut barrier is disrupted in metabolic disorders, followed by permeation of LPS, 28 which was characterized by the decreased levels of occludin and mucin glycoproteins in HFD-fed mice. In the present study, NAC treatment reduced the damage to intestinal integrity and the mucus barrier (Fig. 2) , consistent with the findings of a recent study in which NAC protected radiation-induced mice against disruption of intestinal tight junctions and barrier dysfunction. 29 Emerging evidence supports the notion that endotoxin (LPS) or its binding proteins could be biomarkers of gut bacterial dysbiosis. 30 Therefore, in the present study we focused on an analysis of gut microbiota structure in HFD-fed mice with or without NAC treatment. For some diversity indices, such as the number of OTUs and species observed, there was no difference between the NCD and HFD groups, as reported by others. [31] [32] [33] In the present study, NAC treatment increased the richness and diversity of intestinal bacteria in mice with or without HFD feeding (Fig. S2) . Further, distinct microbial clustering was seen for gut microbiota in mice fed different diets with or without NAC treatment (Fig. 3a,b) . This suggests that both diet and NAC treatment can affect the gut microbiota community in mice.
Figure 5
Differences in the abundance of bacterial families that comprise the gut microbial community (relative to total bacteria) in mice fed a normal chow diet (NCD), a high-fat diet (HFD), NCD plus N-acetylcysteine (NAC; 1 mg/mL, in drinking water) or HFD plus NAC for 5 months. The relative abundance of each family was tabulated on a heat map plotted using the R package (R Foundation for Statistical Computing, Vienna, Austria). The tree structure on the left of the heat map indicates the clustering information for each family. Asterisk next to family names indicate significant differences between the HFD-NAC and HFD groups (P < 0.05).
To delineate which intestinal bacteria led to differences in microbial clustering, we analyzed the structural composition of the microbiota communities in each experimental group at the phylum level. Based on the β-diversity analysis, NAC treatment markedly increased the proportion of Firmicutes, Verrucomicrobia, and Actinobacteria, and reduced the abundance of Bacteroidetes and Proteobacteria in HFD-fed mice (Fig. 3c) . Thus far, there is no conclusion regarding the Firmicutes/Bacteroidetes (F/B) ratio for obese or diabetic individuals. 34 Some studies have reported that there is a positive relationship between F/B ratio and obesity, 35 whereas others have reported that the F/B ratio might not have any function in human obesity. 36 There are also reports that the F/B ratio is lower in obese mice or people. 37, 38 Considering that microbial analyses at the phylum level are not enough to fully reflect bacterial composition, we further compared the Figure 6 (a) Linear discriminant analysis effect size (LEfSe) taxonomic cladogram showing the greatest differences among mice fed a normal chow diet (NCD), a high-fat diet (HFD), NCD plus Nacetylcysteine (NAC; 1 mg/mL, in drinking water) or HFD plus NAC for 5 months. Dot sizes are proportional to the abundance of certain taxa. (b) Greatest differences among the four groups after linear discriminant analysis (LDA) using a threshold score of >4.0. composition of gut bacteria at the genus and family levels. Among the bacteria that were changed in HFDfed mice after NAC treatment (Figs 4-5) , Akkermansia, Bifidobacterium, and Lactobacillus have been proposed as beneficial bacteria for their favorable effects on host metabolism. 10, 39 In contrast, the abundance of Allobaculum is usually decreased in HFD-fed mice, 40 and evidence suggests that Allobaculum is the main contributor to reducing glucose digestion of the host. 41 In addition, Desulfovibrio is considered to be positively correlated with obesity and chronic low-grade inflammation, 42, 43 whereas Blautia is responsible for the occurrence of non-alcoholic fatty liver disease. 44 These reports are consistent with the findings of the present study that NAC increases the Akkermansia, Bifidobacterium, Lactobacillus, and Allobaculum populations, but suppresses the growth of Desulfovibrio and Blautia. This is further supported by a study in which NAC upregulated the amount of Lactobacillus and Bifidobacterium and decreased the abundance of Figure 7 Functional prediction of altered gut microbiota based on Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) 21 analysis between (a) mice fed a normal chow diet (NCD) and those fed high-fat diet (HFD) and (b) mice fed an HFD and N-acetylcysteine (NAC)-treated HFD-fed mice. There were significantly changes in 19 KEGG pathways in HFD versus NCD group (a), 14 of which were reversed following NAC treatment of HFD-fed mice (b). CoA, coenzyme A; EC, epithelial cell.
Figure 8
Spearman's correlation analyses between gut microbial abundance and metabolic biomarkers in experiment groups. BW, body weight gain; glucose, blood glucose concentrations; IGTT AUC, area under the curve for the intraperitoneal glucose tolerance test; WAT, white adipose tissue (mainly epididymis and mesenteric adipose tissues); LPS, circulating lipopolysaccharide. Asterisks indicate significance following Spearman correlation and false discovery rate correlation for multiple comparisons (*P < 0.05, **P < 0.01).
Escherichia coli in weaned piglets. 18 Of note, in the present study the above genera were determined to be closely associated with hyperglycemia, high endotoxin, and intestinal integrity using correlation analyses (Fig. 8 ). Thus, it is possible that the gut microbiota may play a key role in the effects of NAC on glucose metabolic disorders in HFD-fed mice.
To further explore which metabolic pathways of the gut microbiota could be involved in therapeutic effect of NAC, PICRUSt analysis was performed. The findings indicated that NAC directly inhibited bacterial motility and reduced the chance of pathogenic invasion (Fig. 7) , consistent with a report that NAC inhibited the production of extracellular polysaccharide and reduced bacterial adhesion. 45 The study of Volgers et al. 46 also demonstrated that NAC repressed membrane vesicle formation and attenuated pathogenic capacity. In addition, the present study showed that NAC treatment interfered with metabolism-related biosynthesis and the redox system of intestinal bacteria in HFD-fed mice (Fig. 7) . In another study, NAC was found to alleviate oxidative damage in diabetic rats. 47 Based on these findings, we propose that NAC may block the critical metabolic pathways of pathogenic bacteria to promote the growth of beneficial bacteria in HFD-fed mice.
In conclusion, we found that NAC profoundly ameliorated the glucose intolerance and gut barrier disruption, and suppressed inflammatory responses in HFD-fed mice. The potential regulatory mechanism may contribute to the reshaping of altered gut community structure by boosting the growth of beneficial bacteria, such as Akkermansia, Bifidobacterium, Lactobacillus and Allobaculum, and reducing the abundances of harmful bacteria, such as Desulfovibrio and Blautia, which paralleled the restoration of damaged metabolic pathways (Fig. 9 ). The present study may provide a novel insight into the future therapeutic applications of NAC for metabolic diseases. Schematic diagram showing how N-acetylcysteine (NAC) treatment improves disturbances in glucose metabolism of high-fat diet (HFD)-fed mice, and the potential regulatory mechanism involved. First, NAC treatment promotes the growth of beneficial bacteria, such as Akkermansia, Bifidobacterium, Lactobacillus, and Allobaculum, and reduces the abundance of harmful bacteria, including Desulfovibrio and Blautia. Second, NAC treatment may restore the disrupted metabolic pathways of intestinal bacteria in HFD-fed mice. Third, NAC treatment decreases blood glucose concentrations and reverses overweight in HFD-fed mice, accompanied by blockade of inflammation. Red arrows indicate changes in the HFD-fed mice compared with mice fed a normal chow diet (NCD); blue arrows indicate changes in NAC-treated HFDfed mice compared with the HFD group.
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